## Steven Kesten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5039816/publications.pdf

Version: 2024-02-01

118 10,357 49 101 papers citations h-index g-index

119 119 119 119 5547

times ranked

docs citations

all docs

citing authors

#	Article	IF	CITATIONS
1	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554.	27.0	1,969
2	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, The, 2009, 374, 1171-1178.	13.7	430
3	A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol. Chest, 2002, 122, 47-55.	0.8	428
4	Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator. Annals of Internal Medicine, 2005, 143, 317.	3.9	404
5	Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD. Chest, 2005, 127, 809-817.	0.8	349
6	Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD. Chest, 2005, 128, 1168-1178.	0.8	291
7	Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *. Chest, 2003, 124, 1743-1748.	0.8	278
8	Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 948-955.	5.6	252
9	Adverse effects of inhaled corticosteroids. American Journal of Medicine, 1995, 98, 196-208.	1.5	239
10	Infection with <i>Burkholderia cepacia</i> in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 43-48.	5.6	229
11	Medical Personnel's Knowledge of and Ability to Use Inhaling Devices. Chest, 1994, 105, 111-116.	0.8	226
12	Cardiovascular Safety of Tiotropium in Patients With COPD. Chest, 2010, 137, 20-30.	0.8	185
13	Bronchiolitis Obliterans After Lung Transplantation. Chest, 1998, 114, 1411-1426.	0.8	180
14	Risk Indexes for Exacerbations and Hospitalizations Due to COPD. Chest, 2007, 131, 20-28.	0.8	180
15	Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 1995, 96, 571-579.	2.9	163
16	Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses. Chest, 2003, 123, 1441-1449.	0.8	157
17	Pooled Clinical Trial Analysis of Tiotropium Safety. Chest, 2006, 130, 1695-1703.	0.8	156
18	Psychological Functioning and Quality of Life in Lung Transplant Candidates and Recipients. Chest, 2000, 118, 408-416.	0.8	153

#	Article	IF	Citations
19	Clinical Trial Design Considerations in Assessing Longâ€Term Functional Impacts of Tiotropium in COPD: The Uplift Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 303-312.	1.6	152
20	Comparison of Hallway and Treadmill Six-minute Walk Tests. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1540-1543.	5.6	151
21	Aspergillus INFECTION IN SINGLE AND DOUBLE LUNG TRANSPLANT RECIPIENTS. Transplantation, 1996, 61, 915-919.	1.0	146
22	Exacerbation frequency and course of COPD. International Journal of COPD, 2012, 7, 653.	2.3	138
23	Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema. European Respiratory Journal, 2012, 39, 1326-1333.	6.7	134
24	Physician Perceptions and Management of COPD. Chest, 1993, 104, 254-258.	0.8	126
25	LYMPHOCYTIC AIRWAY INFILTRATION AS A PRECURSOR TO FIBROUS OBLITERATION IN A RAT MODEL OF BRONCHIOLITIS OBLITERANS1,2. Transplantation, 1997, 64, 311-317.	1.0	107
26	Effective Delivery of Particles with the HandiHaler $\hat{A}^{\odot}$ Dry Powder Inhalation System over a Range of Chronic Obstructive Pulmonary Disease Severity. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2001, 14, 309-315.	1.2	101
27	Mycobacterial Infections in Lung Transplant Recipients. Chest, 1999, 115, 741-745.	0.8	97
28	The Athena trials: Autologous adiposeâ€derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheterization and Cardiovascular Interventions, 2017, 89, 169-177.	1.7	89
29	Is the Short-term Response to Inhaled $\hat{l}^2$ -Adrenergic Agonist Sensitive or Specific for Distinguishing Between Asthma and COPD?. Chest, 1994, 105, 1042-1045.	0.8	87
30	Regular vs as-needed inhaled salbutamol in asthma control. Lancet, The, 1994, 343, 1379-1382.	13.7	86
31	Pharmacist Knowledge and Ability to Use Inhaled Medication Delivery Systems. Chest, 1993, 104, 1737-1742.	0.8	82
32	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research, 2011, 12, 6.	3.6	76
33	Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. International Journal of COPD, 2009, 4, 245.	2.3	72
34	Cause-specific mortality adjudication in the UPLIFT® COPD trial: Findings and recommendations. Respiratory Medicine, 2012, 106, 515-521.	2.9	70
35	Bronchiolitis Obliterans Organizing Pneumonia (BOOP) in Lung Transplant Recipients. Chest, 1996, 110, 1150-1154.	0.8	69
36	Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trial. Respiratory Medicine, 2010, 104, 1495-1504.	2.9	68

#	Article	IF	CITATIONS
37	Quality of Life in Female Lung Transplant Candidates and Recipients. Chest, 1997, 112, 1165-1174.	0.8	67
38	Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT® Trial. Lung, 2011, 189, 261-268.	3.3	64
39	Diaphragmatic paralysis: A complication of lung transplantation. Annals of Thoracic Surgery, 1996, 61, 170-173.	1.3	63
40	Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. International Journal of COPD, 2008, Volume 3, 127-136.	2.3	62
41	Factors Associated With Emergency Department Dependence of Patients With Asthma. Chest, 1997, 111, 290-295.	0.8	61
42	CYTOLYTIC THERAPY FOR THE TREATMENT OF BRONCHIOLITIS OBLITERANS SYNDROME FOLLOWING LUNG TRANSPLANTATION. Transplantation, 1996, 61, 427-430.	1.0	59
43	Efficacy of Bronchoscopic Thermal Vapor Ablation and Lobar Fissure Completeness in Patients with Heterogeneous Emphysema. Respiration, 2012, 83, 400-406.	2.6	57
44	Impaired Exercise Capacity in Adults with Moderate Scoliosis*. Chest, 1991, 99, 663-666.	0.8	56
45	Tiotropium HandiHaler® in the treatment of COPD: A safety review. International Journal of COPD, 2009, 4, 397.	2.3	56
46	The Placebo Effect in Asthma Drug Therapy Trials: A Meta-Analysis. Journal of Asthma, 2000, 37, 303-318.	1.7	54
47	Variability in Performance of Timed Walk Tests in Pulmonary Rehabilitation Programs. Chest, 2000, 118, 98-105.	0.8	52
48	Cytomegalovirus Viremia in Lung Transplant Recipients Receiving Ganciclovir and Immune Globulin. Chest, 1998, 113, 924-932.	0.8	51
49	Absence of Electrocardiographic Findings and Improved Function with Once-Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. Pharmacotherapy, 2005, 25, 1708-1718.	2.6	51
50	The Localized Inflammatory Response to Bronchoscopic Thermal Vapor Ablation. Respiration, 2013, 86, 324-331.	2.6	51
51	Prior Diagnosis and Treatment of Patients With Normal Results of Methacholine Challenge and Unexplained Respiratory Symptoms. Chest, 1996, 109, 697-701.	0.8	49
52	Bronchial Hyperreactivity after Lung Transplantation Predicts Early Bronchiolitis Obliterans. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 2034-2039.	5.6	48
53	INFECTIONS IN LUNG TRANSPLANT RECIPIENTS. Clinics in Chest Medicine, 1997, 18, 339-351.	2.1	47
54	Patient Handling of a Multidose Dry Powder Inhalation Device for Albuterol. Chest, 1994, 105, 1077-1081.	0.8	45

#	Article	IF	CITATIONS
55	Respiratory Rate during Acute Asthma. Chest, 1990, 97, 58-62.	0.8	43
56	Response Characteristics of a Dual Transcutaneous Oxygen/Carbon Dioxide Monitoring System. Chest, 1991, 99, 1211-1215.	0.8	43
57	Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology, 2011, 16, 825-835.	2.3	43
58	Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD. Chest, 2013, 144, 490-497.	0.8	42
59	Efficacy of Tiotropium in COPD Patients with FEV1 ≥ 60% Participating in the UPLIFT® Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 289-296.	1.6	41
60	Prehospitalization Inhaled Corticosteroid Use in Patients With COPD or Asthma. Chest, 1997, 111, 296-302.	0.8	40
61	Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance. International Journal of COPD, 2008, Volume 3, 771-780.	2.3	40
62	Healthcare Costs with Tiotropium Plus Usual Care versus Usual Care Alone Following 1 Year of Treatment in Patients with Chronic Obstructive Pulmonary Disorder (COPD). Pharmacoeconomics, 2004, 22, 741-749.	3.3	39
63	Comparative Safety of Long-Acting Inhaled Bronchodilators. Drug Safety, 2007, 30, 1151-1160.	3.2	39
64	Aprotinin reduces blood loss in lung transplant recipients. Annals of Thoracic Surgery, 1995, 59, 877-879.	1.3	36
65	Skeletal muscle dysfunction in lung transplantation. Journal of Heart and Lung Transplantation, 2000, 19, 392-400.	0.6	35
66	The Effect of Structured Versus Conventional Inhaler Education in Medical Housestaff. Journal of Asthma, 1996, 33, 385-393.	1.7	34
67	Effect of obesity on constant workrate exercise in hyperinflated men with COPD. BMC Pulmonary Medicine, 2010, 10, 33.	2.0	33
68	Trends in asthma and chronic obstructive pulmonary disease therapy in Canada, 1985 to 1990. Journal of Allergy and Clinical Immunology, 1993, 92, 499-506.	2.9	32
69	Prospective Assessment of a Standardized Pathologic Grading System for Acute Rejection in Lung Transplantation. Chest, 1993, 103, 1813-1818.	0.8	31
70	Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema. International Journal of COPD, 2012, 7, 397.	2.3	31
71	The Acute Effects of Nasal Positive Pressure Ventilation in Patients With Advanced Cystic Fibrosis. Chest, 1998, 113, 1013-1018.	0.8	29
72	Assessment of an Ambulatory Care Asthma Program. Journal of Asthma, 1994, 31, 291-300.	1.7	25

#	Article	IF	Citations
73	Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 104-110.	2.3	25
74	Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respiratory Research, 2011, 12, 129.	3.6	25
75	NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE IN PNEUMOCYSTIS CARINH PNEUMONIA. Lancet, The, 1988, 332, 1414-1415.	13.7	24
76	PULMONARY REHABILITATION AND SURGERY FOR END–STAGE LUNG DISEASE. Clinics in Chest Medicine, 1997, 18, 173-181.	2.1	24
77	Development and implementation of treadmill exercise testing protocols in COPD. International Journal of COPD, 2010, 5, 375.	2.3	23
78	Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine, 2012, 106, 1413-1420.	2.9	23
79	Effects of High-Dose Inhaled Fluticasone Propionate via Spacer on Cell-Mediated Immunity in Healthy Volunteers. Chest, 2000, 118, 1042-1048.	0.8	22
80	Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine, 2006, 100, 1495-1503.	2.9	22
81	Insurance Status and Patient Behavior with Asthma Medications. Journal of Asthma, 2003, 40, 789-793.	1.7	21
82	Development of Nonspecific Interstitial Pneumonitis Associated With Long-term Treatment of Primary Pulmonary Hypertension With Prostacyclin. Chest, 1999, 116, 566-569.	0.8	20
83	Premature discontinuation during the UPLIFT study. Respiratory Medicine, 2011, 105, 1523-1530.	2.9	20
84	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research, 2012, 13, 66.	3.6	20
85	Eletrocardiographic Monitoring in COPD Patients Receiving Tiotropium. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 181-190.	1.6	19
86	Evaluation of withdrawal of maintenance tiotropium in COPD. Respiratory Medicine, 2009, 103, 1415-1420.	2.9	18
87	Evaluation of pulsed electromagnetic field therapy for the treatment of chronic postoperative pain following lumbar surgery: a pilot, double-blind, randomized, sham-controlled clinical trial. Journal of Pain Research, 2018, Volume 11, 1209-1222.	2.0	17
88	A Retrospective Comparative Study of In-hospital Management of Acute Severe Asthma: 1984 vs 1989. Chest, 1993, 103, 1655-1661.	0.8	16
89	Gas Trapping as a Predictor of Positive Methacholine Challenge in Patients With Normal Spirometry Results. Chest, 1995, 107, 992-995.	0.8	16
90	Health-Care Utilization After Near-Fatal Asthma. Chest, 1995, 107, 1564-1569.	0.8	16

#	Article	IF	Citations
91	Bronchodilator Response at Low Lung Volumes Predicts Bronchiolitis Obliterans in Lung Transplant Recipients. Chest, 1996, 109, 405-407.	0.8	16
92	Lung Volume Reduction Surgery. Chest, 1998, 113, 896-899.	0.8	16
93	Asthma and Allergy Avoidance Knowledge and Behavior in Postpartum Women. Annals of Allergy, Asthma and Immunology, 1997, 79, 35-42.	1.0	14
94	Loss of pulmonary function gains after lung volume reduction surgery. Journal of Heart and Lung Transplantation, 1999, 18, 266-268.	0.6	14
95	Performance During Constant Workrate Cycling Exercise in Women with COPD and Hyperinflation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 340-351.	1.6	14
96	Analysis of the T cell receptor Vgamma region gene repertoire in bronchoalveolar lavage (BAL) and peripheral blood of atopic asthmatics and healthy subjects. Clinical and Experimental Immunology, 1996, 104, 144-153.	2.6	12
97	Rationale for the Development and the Mechanism of Action of Endoscopic Thermal Vapor Ablation (InterVapor) for the Treatment of Emphysema. Journal of Bronchology and Interventional Pulmonology, 2012, 19, 237-245.	1.4	12
98	Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research, 2008, 152, 88-94.	5.0	11
99	Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2009, 22, 587-592.	2.6	11
100	Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. International Journal of COPD, 2007, 2, 157-67.	2.3	10
101	Lack of Left Ventricular Dysfunction Associated with Sustained Exposure to Hyperlipidemia Following Lung Transplantation. Chest, 1997, 112, 931-936.	0.8	9
102	Comparison of human lung tissue mass measurements from Ex Vivo lungs and high resolution CT software analysis. BMC Pulmonary Medicine, 2012, 12, 18.	2.0	9
103	Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of COPD, 2009, 4, 119-25.	2.3	9
104	Management of Chronic Obstructive Pulmonary Disease. Drugs, 1989, 38, 160-174.	10.9	8
105	Consideration of Public Programs and Techniques for Public/Community Health Education. Chest, 1994, 106, 274S-278S.	0.8	8
106	Comorbidities in end-stage lung disease. Journal of Heart and Lung Transplantation, 1999, 18, 891-903.	0.6	6
107	Risk of Major Adverse Cardiovascular Events With Inhaled Anticholinergics in Patients With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2009, 301, 1223.	7.4	6
108	Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. International Journal of COPD, 2011, 6, 269.	2.3	6

#	Article	IF	CITATIONS
109	Asthma Education. Chest, 1995, 107, 893-894.	0.8	5
110	Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing. Pulmonary Pharmacology and Therapeutics, 2018, 53, 27-32.	2.6	5
111	Thermal effect of endoscopic thermal vapour ablation on the lung surface in human ex vivo tissue. International Journal of Hyperthermia, 2012, 28, 466-472.	2.5	4
112	Evaluation of Energy in Heated Water Vapor for the Application of Lung Volume Reduction in Patients with Severe Emphysema. Respiration, 2013, 85, 493-499.	2.6	4
113	Chronic Obstructive Pulmonary Disease in a Managed-Care Setting. Disease Management and Health Outcomes, 2001, 9, 589-599.	0.4	3
114	How much lift to the UPLIFT study? – Authors' reply. Lancet, The, 2010, 375, 198.	13.7	3
115	Part III. Advances in lung transplantation. Disease-a-Month, 1999, 45, 101-114.	1.1	2
116	Diagnosis of Primary Hyperventilation Syndrome by Polysomnography: A Report of Two Cases. Canadian Respiratory Journal, 1996, 3, 199-201.	1.6	0
117	End-Stage Lung Disease and Prediction of Mortality. Seminars in Respiratory and Critical Care Medicine, 1996, 17, 423-435.	2.1	0
118	Response to Dr. Tsakok's letter to the editor entitled "Comment on tiotropium― Respiratory Medicine, 2010, 104, 1389.	2.9	0